News

BIO-CAT Grows in Zion Crossroads

BIO-CAT, Inc., a biotechnology company that specializes in enzymes and other advanced microbial solutions, plans to add at least 30,000 square feet to its fermentation facilities in Zion Crossroads. The expansion is projected to start in 2022. The company will add several new jobs and is considering building another 30,000-square-foot section in a second phase.

“Louisa County has partnered with BIO-CAT from the very beginning – they understand not only the economic value that [we bring] to the county, but the overall benefit this expansion can bring to the local community,” said Stephen Schuler, associate vice president of operations.

“It is very rewarding to witness a Louisa business and industry leader grow and thrive locally to meet the demands of their global customers,” said Bob Babyok, Louisa County Board of Supervisors chairman (Green Springs District).

“Similar to brewing and distilling fermentation processes, microbial fermentation can be costly; it requires substantial customization of both building design and equipment. Custom fermentation tanks, stainless steel piping, centrifuges, spray dryers, storage tanks and other unique equipment will be installed at the site, all of which require federal Food and Drug Administration oversight and regular inspections.

“Whether developing beneficial bacteria like probiotics for the human digestive system and production animal feed or developing the right strains to amend the soil microbiome for agriculture, we are developing amazing proprietary solutions for the future,” BIO-CAT Chief Executive Officer and Co-Founder Chris Schuler said.

“BIO-CAT’s financial commitment in this expansion and creation of new job opportunities for our citizens is critical to local economic growth and success,” said Supervisor Fitzgerald Barnes, who represents the Patrick Henry District where the company is located.

BIO-CAT recently celebrated 33 years of industry leadership, during the same year that the company lost its co-founder, Ed Schuler, at the age of 89. Ed, his son Chris and partner Brian Huffman founded the company in 1988.

The firm has doubled its business every five years and is involved in human nutrition, animal nutrition, and crop science. As the company’s revenue has grown, so has its presence in Louisa County. What started as a 12,000-square-foot building has since expanded to over 90,000 square feet.

In 2005, Chris Schuler decided to expand the business portfolio from a pure focus on enzymes, to producing and fermenting probiotics, via an acquisition of a biotech company in Minnesota. After 15 years of success in Minnesota, the company plans to expand that business through the expansion in Zion Crossroads.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business